Dr Eleftheria Galatou

Dr Eleftheria Galatou holds 2 Bachelor diplomas in Biology and Pharmacy of the Aristotle University of Thessaloniki. In 2009 she completed her Master thesis in “Applied Genetics and Biotechnology”. In 2014, she completed her doctoral thesis in Molecular Physiology and Pharmacology in the Department of Physiology and Molecular Biology, School of Biology, Aristotle University of Thessaloniki. During her PhD period, as a Research Assistant in the School of Biology, Aristotle University of Thessaloniki (AUTH), she has been actively involved in the practical training courses of “Animal Physiology” and “Molecular Biology” for the undergraduate Biology students. Moreover, she has been acting in supervising both undergraduate and graduate students upon executing their Diploma and MSc theses, respectively, in the lab of Animal Physiology, School of Biology, AUTH. This training involved teaching on the principles and various related to molecular physiology techniques for more than 6 years. Her post-doctoral research was focused on “preclinical studies of the therapeutic role of PPARs (Peroxisome Proliferator-Activated Receptors) in heart failure”. Since September 2016, she is a lecturer of Molecular Pharmacology, Pharmacogenomics and Clinical Pharmacy and Therapeutics at the University of Nicosia. Dr Eleftheria Galatou has authored/co-authored several research publications published invalid international scientific journals and conference proceedings.

During her research career, she was involved in in vitro and in vivo experimental models. Specifically, she focused on the isolation and culture of primary cardiac myocytes in combination with molecular biology techniques (PCR, real-time PCR, flow cytometry, Western blotting), biochemistry (enzyme activity measurement, histology, immunohistochemistry, heart perfusion, ischemia-reperfusion techniques, electrocardiography) and modern imaging techniques of living cells. At the same time, he extensively worked with in vivo experimental models of diabetic rats and transgenic mice for the determination of mechanisms of pathogenesis, toxicity and therapeutic applications of new possible pharmaceutical targets.